We Offer Worldwide Shipping
Login Wishlist

Inositol

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-P0647

  • Specification : 98.0%(HPLC)

  • CAS number : 87-89-8

  • PUBCHEM ID : 892

  • Volume : 100mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0647

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

Appearance

White crystalline powder

Botanical Source

Structure Type

Carbohydrates

Category

Standards;Natural Pytochemical;API

SMILES

C1(C(C(C(C(C1O)O)O)O)O)O

Synonyms

INOSITAL/(1R,2S,3r,4R,5S,6s)-Cyclohexane-1,2,3,4,5,6-hexol/Mesoinosite/1,2,3,5/4,6-Inositol/Cyclohexanehexol/Nucite/nositol/Mesoinosit/1,2,3,4,5,6-cyclohexanehexol, (1a,2a,3a,4b,5a,6b)-/INS/Dambose/Inositol (VAN)/myo-Inositol/(1R,2r,3S,4R,5s,6S)-cyclohexane-1,2,3,4,5,6-hexaol/Scyllite/Hexahydroxycyclohexane/Inositene/Inositina/Rat Antispectacled Eye Factor/MI/Phaseomannitol/MOUSE ANTIALOPECIA FACTOR/bios I/Phaseomannite/Mesoinositol/Myoinosite/Isoinositol/Mesovit/iso-Inositol/(1R,2S,3r,4R,5S,6s)-1,2,3,4,5,6-Cyclohexanehexol/1,2,3,4,5,6-Cyclohexanehexol, (1α,2α,3α,4β,5α,6β)-/Mesol/cis-1,2,3,5-trans-4,6-Cyclohexanehexol/2-(PROPYLAMINO)-M-PROPIONOTOLUIDIDE HYDROCHLORIDE/meso-inositol/Inosite/i-Inositol

IUPAC Name

cyclohexane-1,2,3,4,5,6-hexol

Applications

i-Inositol is a chemical compound, associated lipids are found in many foods, in particular fruit, especially cantaloupe and oranges.

Density

2.0±0.1 g/cm3

Solubility

Water

Flash Point

143.4±21.9 °C

Boiling Point

291.3±40.0 °C at 760 mmHg

Melting Point

220-228ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2906130000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:87-89-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27717596

Abstract

Studies over the last decade have demonstrated that some polycystic ovary syndrome (PCOS) patients have abnormal insulin sensitivity (insulin resistance), independently from being overweight or obese. This induces the risk of developing type 2 diabetes in such PCOS patients. The use of insulin sensitizers (i.e. metformin), reduces such metabolic, and most hormonal, impairments. As metformin often induces side effects, new integrative strategies have been proposed to treat insulin resistance, such as the use of inositols. Such compounds are mainly represented in humans by two inositol stereoisomers: myo-inositol (MYO) and d-chiro-inositol (DCI). MYO is the precursor of inositol triphosphate, a second messenger that regulates thyroid-stimulating hormone (TSH) and FSH as well as insulin. DCI derives from the conversion of myo-inositol via an insulin-dependent pathway. Several preliminary studies have indicated possible benefits of inositol therapy in PCOS patients, but to date no meta-analysis has been performed. This review aims to give clinical insights for the clinical use of inositol in PCOS.

Copyright © 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

KEYWORDS

anovulation; d-chiro-inositol; diabetes; hyperandrogenism; insulin resistance; myo-inositol

Title

Inositol as putative integrative treatment for PCOS.

Author

Genazzani AD1.

Publish date

2016 Dec

PMID

27351907

Abstract

INTRODUCTION:
Inositol and its derivatives comprise a huge field of biology. Myo-inositol is not only a prominent component of membrane-incorporated phosphatidylinositol, but participates in its free form, with its isomers or its phosphate derivatives, to a multitude of cellular processes, including ion channel permeability, metabolic homeostasis, mRNA export and translation, cytoskeleton remodeling, stress response.

AREAS COVERED:
Bioavailability, safety, uptake and metabolism of inositol is discussed emphasizing the complexity of interconnected pathways leading to phosphoinositides, inositol phosphates and more complex molecules, like glycosyl-phosphatidylinositols.

EXPERT OPINION:
Besides being a structural element, myo-inositol exerts unexpected functions, mostly unknown. However, several reports indicate that inositol plays a key role during phenotypic transitions and developmental phases. Furthermore, dysfunctions in the regulation of inositol metabolism have been implicated in several chronic diseases. Clinical trials using inositol in pharmacological doses provide amazing results in the management of gynecological diseases, respiratory stress syndrome, Alzheimer’s disease, metabolic syndrome, and cancer, for which conventional treatments are disappointing. However, despite the widespread studies carried out to identify inositol-based effects, no comprehensive understanding of inositol-based mechanisms has been achieved. An integrated metabolomics-genomic study to identify the cellular fate of therapeutically administered myo-inositol and its genomic/enzymatic targets is urgently warranted.

KEYWORDS

Myo-inositol; cell signalling; inositol phosphates; inositolphosphoglycans; phosphoinositides

Title

Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease.

Author

Bizzarri M1,2, Fuso A2,3, Dinicola S4,5, Cucina A5,6, Bevilacqua A7.

Publish date

2016 Oct

PMID

27595157

Abstract

Inositol is an organic compound of high biological importance that is widely distributed in nature. It belongs to the sugar family and is mainly represented by its two dominant stereoisomers: myo-inositol and D-chiro-inositol that are found in the organism in the physiological serum ratio 40:1. Inositol and its derivatives are important components of the structural phospholipids of the cell membranes and are precursors of the second messengers of many metabolic pathways. A high concentration of myoinositol is found in the follicular fluid and in semen. Inositol deficiency and the impairment of the inositol-dependent pathways may play an important role in the pathogenesis of insulin resistance and hypothyroidism. The results of the research also point out the potential beneficial role of inositol supplementation in polycystic ovarian syndrome and in the context of assisted reproduction technologies and in vitro fertilization. The main aim of the article is to overview the major inositol-dependent metabolic pathways and to discuss its importance for reproduction.

KEYWORDS

Assisted reproductive technologies; D-chiro-inositol; insulin resistance; myo-inositol; polycystic ovary syndrome

Title

Inositol and human reproduction. From cellular metabolism to clinical use.

Author

Milewska EM1, Czyzyk A1, Meczekalski B1, Genazzani AD2.

Publish date

2016 Sep